Erschienen in:
04.08.2020 | Correction
Correction to: Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)
verfasst von:
Tomoro Hishiki, Kimikazu Matsumoto, Miki Ohira, Takehiko Kamijo, Hiroyuki Shichino, Tatsuo Kuroda, Akihiro Yoneda, Toshinori Soejima, Atsuko Nakazawa, Tetsuya Takimoto, Isao Yokota, Satoshi Teramukai, Hideto Takahashi, Takashi Fukushima, Takashi Kaneko, Junichi Hara, Michio Kaneko, Hitoshi Ikeda, Tatsuro Tajiri, Akira Nakagawara, For the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)
Erschienen in:
International Journal of Clinical Oncology
|
Ausgabe 9/2020
Einloggen, um Zugang zu erhalten
Excerpt
In the October 2018 issue of International Journal of Clinical Oncology, in the article titled “Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)” (volume 23, pages 965–973; doi:
https://doi.org/10.1007/s10147-018-1281-8.), by Hishiki T et al., there was a printing error in Figure 1. In the description for the schedule of the induction regime 05A1 and 05A3, the arrow that shows the day of pirarubicin administration was intended to indicate day 3, but in error had been published with the arrows indicating purarubicin administration on day 2. …
